This study aimed to explore the relationship between systemic lupus erythematosus (SLE) and osteoporosis (OP) based on bioinformatics.
Methods
The expression profiles of SLE and OP gene chips were searched through the GEO database, and the differentially expressed genes (DEGs) were screened out to obtain the intersection. Then, the Funrich software was used to predict the upstream miRNAs of the intersection genes, and the miRNA–mRNA relationship network was constructed. Afterward, the String database and Cytoscape software were used to construct the protein interaction network of the intersection genes to screen out the key genes. Finally, the functions and related pathways of key genes were analyzed by using the DAVID database.
Results
①A total of 140 intersection genes of SLE and OP were obtained; ②There were 217 miRNAs regulating the intersection genes; ③IL-4, FOS, TLR1, TLR6, CD40LG, CCR1 were the key genes in the protein interaction network; ④The DAVID enrichment analysis mainly covered the positive regulation of cytokine production, the regulation of osteoclast differentiation, macrophage activation and other biological processes, involving Toll-like receptor signaling pathway, T cell receptor signaling pathway, Th1, Th2, and Th17 cells Differentiation, IL-17 signaling pathway.
Conclusions
SLE and OP still have some highly overlapping differential gene expressions under the background of complex gene networks. The gene functions and signaling pathways involved can simultaneously regulate the two diseases, suggesting that there is a close relationship between the molecular mechanisms of the two diseases, and that it may be a target of drugs that interfere with two diseases at the same time.
Chinese Rheumatology Association. National clinical research center for dermatologic and immunologic diseases; chinese systemic lupus erythematosus treatment and research group. Zhonghua Nei Ke Za Zhi2020; 59(3): 172–185.
2.
TanakaYO'NeillSLiM, et al.Systemic lupus erythematosus: targeted literature review of the epidemiology, current treatment, and disease burden in the Asia Pacific region. Arthritis Care Res2020. DOI: 10.1002/acr.24431.
3.
CarterEEBarrSGClarkeAE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol2016; 12(10): 605–620.
4.
KanisJACooperCCooperC, et al.European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int2019; 30(1): 3–44.
5.
ZengQLiNWangQ, et al.The prevalence of osteoporosis in China, a nationwide, multicenter DXA survey. J Bone Mineral Res2019; 34(10): 1789–1797.
6.
JungJ-YChoiSTParkS-H, et al.Prevalence of osteoporosis in patients with systemic lupus erythematosus: A multicenter comparative study of the World Health Organization and fracture risk assessment tool criteria. Osteoporos Sarcopenia2020; 6(4): 173–178.
7.
GuCZhaoRZhangX, et al.A meta-analysis of secondary osteoporosis in systemic lupus erythematosus: prevalence and risk factors. Arch Osteoporos2019; 15(1): 1.
8.
BultinkIEM. Bone disease in connective tissue disease/systemic lupus erythematosus. Calcified Tissue Int2018; 102(5): 575–591.
9.
YamamotoKKishinoMNakamuraS, et al.Symptoms and upper gastrointestinal mucosal injury associated with bisphosphonate therapy. Intern Med2019; 58(8): 1049–1056.
10.
de Sales LimaMVRizzatoJGracindo MarquesDV, et al.Denosumab related osteonecrosis of jaw: a case report. J Oral Maxillofacial Research2018; 9(4): e5. Published
11.
PatopILWüstSKadenerS. Past, present, and future of circRNAs. EMBO Journal2019; 38(16): e100836.
12.
YuanSTangCChenD, et al.miR-98 modulates cytokine production from human PBMCs in systemic lupus erythematosus by targeting IL-6 mRNA. J Immunology Research2019; 2019: 9827574.
13.
YuLLiuY. circRNA_0016624 could sponge miR-98 to regulate BMP2 expression in postmenopausal osteoporosis. Biochem Biophysical Res Commun2019; 516(2): 546–550.
14.
AliRHammadAEl-NahreryE, et al.Serum RANKL, osteoprotegerin (OPG) and RANKL/OPG ratio in children with systemic lupus erythematosus. Lupus2019; 28(10): 1233–1242.
15.
CaielliSVeigaDTBalasubramanianP, et al.A CD4+ T cell population expanded in lupus blood provides B cell help through interleukin-10 and succinate. Nat Med2019; 25(1): 75–81.
16.
ReadKAPowellMDSreekumarBK, et al.In Vitro Differentiation of Effector CD4+ T Helper Cell Subsets. Mouse Models Innate Immun2019; 1960: 75–84.
17.
Mohammadoo-KhorasaniMSalimiSTabatabaiE, et al.Interleukin-1β (IL-1β) & IL-4 gene polymorphisms in patients with systemic lupus erythematosus (SLE) & their association with susceptibility to SLE. Indian Journal Medical Research2016; 143(5): 591–596.
18.
KogaTIchinoseKKawakamiA, et al.The role of IL-17 in systemic lupus erythematosus and its potential as a therapeutic target. Expert Rev Clin Immunol2019; 15(6): 629–637.
19.
TalaatRMMohamedSFBassyouniIH, et al.Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity. Cytokine2015; 72(2): 146–153.
20.
ZhouHHuBHuangN, et al.Aberrant T cell subsets and cytokines expression profile in systemic lupus erythematosus. Clin Rheumatol2018; 37(9): 2405–2413.
21.
KuwabaraTIshikawaFKondoM, et al.The Role of IL-17 and related cytokines in inflammatory autoimmune diseases. Mediators Inflammation2017; 2017: 3908061.
22.
ChenS-YLiuM-FKuoP-Y, et al.Upregulated expression of STAT3/IL-17 in patients with systemic lupus erythematosus. Clin Rheumatol2019; 38(5): 1361–1366.
23.
DasASinhaMDattaS, et al.Monocyte and macrophage plasticity in tissue repair and regeneration. Am Journal Pathology2015; 185(10): 2596–2606.
24.
UzrailAHAssafAMAbdallaSS. Correlations of expression levels of a panel of genes (IRF5, STAT4, TNFSF4, MECP2, and TLR7) and Cytokine Levels (IL-2, IL-6, IL-10, IL-12, IFN-γ, and TNF-α) with systemic lupus erythematosus outcomes in jordanian patients. Biomed Research International2019; 2019: 1703842.
25.
AziziehFRaghupathyRShehabD, et al.Cytokine profiles in osteoporosis suggest a proresorptive bias. Menopause2017; 24(9): 1057–1064.
26.
AziziehFYShehabDAl JarallahK, et al.Circulatory pattern of cytokines, adipokines and bone markers in postmenopausal women with low BMD. J Inflamm Res2019; 12: 99–108.
27.
ZhangJShiHZhangN, et al.Interleukin-4-loaded hydrogel scaffold regulates macrophages polarization to promote bone mesenchymal stem cells osteogenic differentiation via TGF-β1/Smad pathway for repair of bone defect. Cel Proliferation2020; 53(10): e12907.
28.
YangD-HYangM-Y. The role of macrophage in the pathogenesis of osteoporosis. Int J Mol Sci2019; 20(9): 2093.
29.
DouCDingNZhaoC, et al.Estrogen deficiency-mediated M2 macrophage osteoclastogenesis contributes to M1/M2 ratio alteration in ovariectomized osteoporotic mice. J Bone Mineral Res2018; 33(5): 899–908.
30.
LiangC-LJiangHFengW, et al.Total Glucosides of Paeony Ameliorate Pristane-Induced Lupus Nephritis by Inducing PD-1 ligands+ Macrophages via Activating IL-4/STAT6/PD-L2 Signaling. Front Immunol2021; 12: 683249.
31.
KatsuyamaTTsokosGCMoultonVR. Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus. Front Immunol2018; 9: 1088.
32.
XuQJinXZhengM, et al.Phosphatase PP2A is essential for TH17 differentiation. Proc Natl Acad Sci2019; 116(3): 982–987.
33.
DaiHHeFTsokosGC, et al. IL-23 limits the production of IL-2 and promotes autoimmunity in lupus. J Immunol2017; 199: 903–910.
34.
KonoMKuritaTYasudaS, et al.Decreased expression of serine/arginine‐rich splicing factor 1 in T Cells From patients with active systemic lupus erythematosus accounts for reduced expression of RasGRP1 and DNA methyltransferase 1. Arthritis Rheumatol2018; 70(12): 2046–2056.
35.
HeJZhangRShaoM, et al.Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis2020; 79(1): 141–149.
36.
XuCMiaoYPiQ, et al.Fra-2 is a novel candidate drug target expressed in the podocytes of lupus nephritis. Clin Immunol2018; 197: 179–185.
37.
YinZZhuWWuQ, et al.Glycyrrhizic acid suppresses osteoclast differentiation and postmenopausal osteoporosis by modulating the NF-κB, ERK, and JNK signaling pathways. Eur J Pharmacol2019; 859: 172550.
38.
WangDLiJFengW, et al.Ligustilide suppresses RANKL‐induced osteoclastogenesis and bone resorption via inhibition of RANK expression. J Cell Biochem2019; 120(11): 18667–18677.
39.
YimM. The role of toll-like receptors in osteoclastogenesis. J Bone Metab2020; 27(4): 227–235.
40.
KassemALindholmCLernerUH. Toll-Like Receptor 2 Stimulation of Osteoblasts Mediates Staphylococcus Aureus Induced Bone Resorption and Osteoclastogenesis through Enhanced RANKL. PLoS One2016; 11(6): e0156708.
41.
Pérez-FerroMSerrano Del CastilloCSánchez-PernauteO. Cell Membrane-bound TLR2 and TLR4: Potential Predictors of Active Systemic Lupus Erythematosus and Lupus Nephritis. J Rheumatol2016; 43(7): 1444–1445.
42.
HoussenMEEl-MahdyRHShahinDA. Serum soluble toll-like receptor 2: a novel biomarker for systemic lupus erythematosus disease activity and lupus-related cardiovascular dysfunction. Int J Rheum Dis2016; 19(7): 685–692.
43.
MarquesCPCMaorYde AndradeMS, et al.Possible evidence of systemic lupus erythematosus and periodontal disease association mediated by Toll-like receptors 2 and 4. Clin Exp Immunol2016; 183(2): 187–192.
44.
FengXYangRTianY, et al.HMGB1 protein promotes glomerular mesangial matrix deposition via TLR2 in lupus nephritis. J Cell Physiol2020; 235(6): 5111–5119.
45.
BignonAGaudinFHémonP, et al.CCR1 inhibition ameliorates the progression of lupus nephritis in NZB/W mice. J Immunol2014; 192(3): 886–896.
46.
CollinsFLWilliamsJOBloomAC, et al.CCL3 and MMP-9 are induced by TL1A during death receptor 3 (TNFRSF25)-dependent osteoclast function and systemic bone loss. Bone2017; 97: 94–104.
47.
SucurAJajicZArtukovicM, et al.Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells. Arthritis Res Ther2017; 19(1): 142.
48.
WanHQianT-YHuX-J, et al.Correlation of Serum CCL3/MIP-1α Levels with Disease Severity in Postmenopausal Osteoporotic Females. Balkan Med J2018; 35(4): 320–325.
49.
RamanujamMSteffgenJVisvanathanS, et al.Phoenix from the flames: rediscovering the role of the CD40-CD40L pathway in systemic lupus erythematosus and lupus nephritis. Autoimmun Rev2020; 19(11): 102668.
50.
PanachLPinedaBMifsutD, et al.The role of CD40 and CD40L in bone mineral density and in osteoporosis risk: A genetic and functional study. Bone2016; 83: 94–103.
51.
HuangYYinYGuY, et al.Characterization and immunogenicity of bone marrow-derived mesenchymal stem cells under osteoporotic conditions. Sci China Life Sci2020; 63(3): 429–442.
52.
SuXYeLChenX, et al.MiR-199-3p promotes ERK-mediated IL-10 production by targeting poly (ADP-ribose) Polymerase-1 in patients with systemic lupus erythematosus. Chemico-Biological Interactions2019; 306: 110–116.
53.
WalanaWWangJ-JYabasinIB, et al.IL-8 analogue CXCL8 (3-72) K11R/G31P, modulates LPS-induced inflammation via AKT1-NF-kβ and ERK1/2-AP-1 pathways in THP-1 monocytes. Hum Immunol2018; 79(11): 809–816.
54.
SunYLiuW-ZLiuT, et al.Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. J Receptors Signal Transduction2015; 35(6): 600–604.
55.
WuJ-CSunJXuJ-C, et al.Down-regulated microRNA-199a-3p enhances osteogenic differentiation of bone marrow mesenchymal stem cells by targeting Kdm3a in ovariectomized rats. Biochem J2021; 478(4): 721–734.
56.
WangX.ZhangCWuZ, et al.CircIBTK inhibits DNA demethylation and activation of AKT signaling pathway via miR-29b in peripheral blood mononuclear cells in systemic lupus erythematosus. Arthritis Res Ther2018; 20(1): 118.
57.
WangYHanXZangT, et al.miR-29b enhances the proliferation and migration of bone marrow mesenchymal stem cells in rats with castration-induced osteoporosis through the PI3K/AKT and TGF-β/Smad signaling pathways. Exp Therapeutic Medicine2020; 20(4): 3185–3195.
58.
XiaTDongSTianJ. miR-29b promotes the osteogenic differentiation of mesenchymal stem cells derived from human adipose tissue via the PTEN/AKT/β-catenin signaling pathway. Int J Mol Med2020; 46(2): 709–717.
59.
RasmussenTKAndersenTBakRO, et al.Overexpression of microRNA-155 increases IL-21 mediated STAT3 signaling and IL-21 production in systemic lupus erythematosus. Arthritis Res Ther2015; 17(1): 154.
60.
KongJLiLLuZ, et al.MicroRNA-155 Suppresses Mesangial Cell Proliferation and TGF-β1 Production via Inhibiting CXCR5-ERK Signaling Pathway in Lupus Nephritis. Inflammation2019; 42(1): 255–263.
61.
MaoZZhuYHaoW, et al.MicroRNA‐155 inhibition up‐regulates LEPR to inhibit osteoclast activation and bone resorption via activation of AMPK in alendronate‐treated osteoporotic mice. IUBMB Life2019; 71(12): 1916–1928.
62.
XueYFanXYangR, et al.miR-29b-3p inhibits post-infarct cardiac fibrosis by targeting FOS. Biosci Reports2020; 40(9): BSR20201227.
63.
ZhaoLOuyangYBaiY, et al.miR-155-5p inhibits the viability of vascular smooth muscle cell via targeting FOS and ZIC3 to promote aneurysm formation. Eur J Pharmacol2019; 853: 145–152.
